XPhyto Therapeutics is closing the gap between traditional cannabis-based medicine and modern scientific approaches
XPhyto Therapeutics is a science-based cannabis company focusing on medical formulation, clinical validation, and emerging European markets. In fact, the company has a 100% owned German subsidiary, Bunker Pflanzenextrakte GmbH. They’ve been granted a unique German cannabis cultivation and extraction licence for scientific purposes. This was issued by the German Federal Institute for Drugs and Medical Devices (BfArM).
Additionally, XPhyto Laboratories Inc., is a wholly owned subsidiary of XPhyto Therapeutics Corp. In general, they provide certified third party analytical testing (cannabinoids, heavy metals, pesticides, etc.) to Canadian licenced growers, processors, dispensaries, and government agencies.
More on XPhyto Therapeutics
Moreover, XPhyto is pursuing other opportunities in Germany. These include cultivation, processing, manufacturing, import, and distribution. Furthermore, in Canada, two exclusive 5-year engagements with the Faculty of Pharmacy at a major Canadian university provide certified extraction, isolation, and formulation facilities, drug research and development expertise, as well as commercial analytical testing capability.
“The long term vision for XPhyto is to build one of the largest distribution networks in Germany for medical and CBD products”, says CEO and Director, Hugh Rogers.
For more information on XPhyto Therapeutics Corp. (XPHY:CSE) please fill out the form below.